Jin System Submits Preliminary Review Application for KOSDAQ Listing

[Asia Economy Reporter Eunmo Koo] Jin System, which has succeeded in ultra-fast molecular diagnostics by significantly reducing molecular diagnostic test time from 2 hours to within 30 minutes, is challenging a listing on the KOSDAQ market.

Jin System, a rapid molecular diagnostics specialist company, announced on the 23rd that it has submitted a preliminary review application to the Korea Exchange for KOSDAQ listing and has officially begun the initial public offering (IPO) process. Samsung Securities is in charge of the listing underwriting, aiming for a listing in the first half of next year.

Since its establishment in 2010, Jin System has focused on advancing and commercializing rapid molecular diagnostic platform technology and has won the Presidential Award at the Korea Invention Patent Exhibition with its polymerase chain reaction (PCR) technology. Jin System’s molecular diagnostic platform technology is evaluated as a powerful and scalable technology that combines ▶the rapidity of immunodiagnostic technology ▶ease of on-site diagnosis ▶multiplex diagnosis capability, which also enables precise diagnosis possible with existing NGS diagnostic technology. As a result, it has received an A grade from two excellent technology evaluation institutions.

By utilizing Jin System’s rapid molecular diagnostic platform, the test time, which previously took 2 hours, can be shortened to within 30 minutes, enabling rapid confirmation testing of infectious diseases and various on-site tests. Additionally, miniaturization and lightweight design of diagnostic equipment are leading to the commercialization of portable self-diagnostic devices, and the development of multiplex diagnostic kits capable of detecting more than 20 diagnostic targets from a single specimen is also underway.

Yujin Seo, CEO of Jin System, stated, “We will expand our unique rapid molecular diagnostic platform technology not only to the in vitro diagnostics market that requires more accurate and rapid diagnostic testing solutions but also to fields such as companion animal diagnostics, food safety, and raw material inspection. Through future listing, we will drive diversification of the rapid molecular diagnostic platform by continuously investing in research and development and expanding production facilities, and lead sustainable growth through collaboration with domestic and international diagnostic content companies.”

This content was produced with the assistance of AI translation services.